AstraZeneca Pharma India Limited
AstraZeneca Pharma announced the resignation of two senior management personnel: Ayush Kumar Agarwal, Business Unit Director (effective June 12, 2026), and Shikha Mirchandani Chatrath, Director - Commercial Excellence (effective August 3, 2026). The company is seeking replacements.
Jun 01 2026 11:30:13
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Ltd board recommended a final dividend of Rs. 36 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming AGM on August 10, 2026, with payment expected by September 08, 2026.
May 26 2026 20:01:49
AstraZeneca Pharma India Q4 profit drops 23% despite strong revenue growth
AstraZeneca Pharma India reported a 23% decline in its Q4 FY26 net profit, reaching ₹44.9 crore, despite experiencing a 20.8% surge in revenue for the same period.
May 26 2026 19:48:59
AstraZeneca Pharma India Ltd - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
AstraZeneca Pharma India received approval from CDSCO for an additional indication for its drug Calquence® (Acalabrutinib maleate tablets 100 mg). This approval allows the drug to be marketed for previously untreated mantle cell lymphoma, expanding its treatment scope.
May 21 2026 13:26:04
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
AstraZeneca Pharma shareholders approved the relocation of its registered office from Karnataka to Maharashtra, which also requires an amendment to the Memorandum of Association. This change is subject to various regulatory approvals.
May 12 2026 18:57:55
AstraZeneca Pharma India Ltd - 506820 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
AstraZeneca Pharma shareholders have approved the relocation of the company's Registered Office from Karnataka to Maharashtra. This change involves an amendment to the Memorandum of Association and is contingent on obtaining all necessary regulatory approvals.
May 12 2026 13:55:31
Read More